CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
Volume 4.39M
Average 4.99M
CTMX Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
CytomX Therapeutics, Inc.NASDAQ: CTMX
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI turns positive
Q1 FY2026 Accumulated OCI was $102K, compared with -$1K a year earlier. Over 3 fiscal years it compounded at +123.1% a year.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps rising in the next quarterly balance sheet after a +10300.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 111K USD
- Year-over-year change
- +311.1%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 111K | +311.1% |
| FY2024 | 2024-12-31 | 27K | -71.6% |
| FY2023 | 2023-12-31 | 95K | +850.0% |
| FY2022 | 2022-12-31 | 10K | +104.1% |
| FY2021 | 2021-12-31 | (242K) | — |
Accumulated OCI vs competitors
How CTMX compares with its peers on the latest reported figures
- CTMX's Mar 2026 Accumulated OCI of $102K is the highest of the 10 companies compared; the peer median is -$329K.
- Its year-over-year change of +10300.0% is the highest of 10, against a peer median of -263.4%.
- Accumulated OCI amounts to 0.0% of total assets for CTMX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $102K | +10300.0% | +123.1% | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | -$27K | -2600.0% | — | 0.0% | |
| Mar 2026 | -$101K | -1022.2% | — | 0.0% | |
| Aug 2026 | -$210K | -276.5% | — | 0.0% | |
| Sep 2026 | -$329K | -108.7% | +42.2% | 0.0% | |
| Mar 2026 | -$802K | +26.6% | — | 0.3% | |
| Jun 2026 | -$872K | -438.0% | — | 0.1% | |
| Dec 2025 | -$1.91M | -263.4% | — | 2.4% | |
| Sep 2026 | -$6.66M | -10.1% | — | 0.6% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CTMX) | -$329K | -263.4% | +42.2% | 0.0% | |
Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 205.53M | 193.65M | 17.17M | 38.05M | 12.67M |
| Short-term Investments | 99.7M | 0 | 157.34M | 62.57M | 124.39M |
| Net Receivables | 790K | 35.99M | 3.43M | 3.1M | 2.01M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 7.47M | 5M | 3.58M | 4.86M |
| Total Current Assets | 310.3M | 237.1M | 182.94M | 107.31M | 143.92M |
| Property, Plant & Equipment (Net) | 25.32M | 21.02M | 16.18M | 10.6M | 4.7M |
| Goodwill | 949K | 949K | 949K | 949K | 949K |
| Intangible Assets | 1.02M | 875K | 729K | 583K | 438K |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.82M | 944K | 1M | 1.09M | 1.56M |
| Total Non-current Assets | 29.11M | 23.79M | 18.86M | 13.23M | 7.65M |
| Total Assets | 339.41M | 260.89M | 201.79M | 120.53M | 151.57M |
| Account Payables | 2.82M | 2.81M | 1.46M | 1.09M | 1.3M |
| Short-term Debt | 0 | 0 | 0 | 0 | 4.24M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 40.82M | 121.27M | 132.27M | 67.2M | 26.88M |
| Other Current Liabilities | 0 | 0 | 9.44M | 0 | 5.99M |
| Total Current Liabilities | 77.87M | 152.61M | 155.91M | 85.77M | 46.62M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 243.94M | 180.06M | 80.05M | 26.86M | 1.59M |
| Other Non-current Liabilities | 0 | 0 | 3.89M | 4.12M | 4.35M |
| Total Non-current Liabilities | 262M | 194.03M | 93.33M | 35.22M | 5.94M |
| Total Liabilities | 339.87M | 346.64M | 249.24M | 120.99M | 52.56M |
| Common Stock | 1K | 1K | 1K | 1K | 2K |
| Retained Earnings | (623.56M) | (722.88M) | (723.45M) | (691.58M) | (711.95M) |
| Accumulated OCI | (242K) | 10K | 95K | 27K | 111K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (459K) | (85.75M) | (47.45M) | (456K) | 99.01M |
| Total Debt | 21.67M | 18.06M | 13.97M | 9.39M | 4.24M |
| Net Debt | (183.86M) | (175.59M) | (3.2M) | (28.67M) | (8.43M) |
CytomX Therapeutics, Inc.
NASDAQ:CTMX
Intrinsic Alpha fair value
Locked
Current Price
$1.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.